Breast tumor-secreted sADAM10 promotes atrial fibrosis and fibrillation in breast cancer patients independent of treatment, suggesting sADAM10 inhibition as a new AF therapy.
Tumour-secreted sADAM10 promotes atrial fibrillation and fibrogenesis in breast cancer patients, suggesting its inhibition as a potential novel therapeutic target for BC-associated AF.
BC patients before treatment present a significantly higher prevalence of AF and atrial remodelling, which correlate with elevated levels of tumour-originated sADAM10 and ACF-secreted sEphrin B2. Tumour-originated sADAM10 directly promotes AF pathogenesis by inducing atrial fibrosis, independent of cancer treatment. These findings imply that the inhibition of sADAM10 represents a potentially new therapeutic option for BC-associated AF.
“Paracrine mechanisms underlying risk of atrial fibrosis and atrial fibrillation in breast cancer patients: new perspectives in #EHJ!”
Yin et al. (2026) studied this question. Breast tumor-secreted sADAM10 promotes atrial fibrosis and fibrillation in breast cancer patients independent of treatment, suggesting sADAM10 inhibition as a new AF therapy.